Skip to content

PROCESS. TECHNOLOGY. EXPERIENCE.

Quality Solutions Now (QSN) LogoQuality Solutions Now (QSN) Logo
  • Home
  • What We Do
    • How We Make An Impact
    • What Our Clients Say
    • QSN Supplier Listings
  • Our Proprietary Process
  • Our Skilled Consultants
    • Become a QSN Consultant
  • News and Advice
  • Contact
  • FDA’s New Drug Delivery Guidance: Why Performance Requirements Start With Design Controls

    On October 29, 2026, the U.S. Food and Drug Administration (FDA) issued revised draft guidance titled Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products. The guidance addresses how manufacturers [...]

  • FDA’s New Change Control Examples: Why Device Modifications Need a Plan Before They Happen

    On October 20, 2026, the FDA published new hypothetical case examples demonstrating how Predetermined Change Control Plans (PCCPs) can support modifications to medical devices, including devices that use machine learning and continuously evolving software. The [...]

  • FDA Town Hall Takeaways: Biocompatibility Risk Assessment and ISO 10993-1:2025

    On September 9, 2026, FDA’s Center for Devices and Radiological Health (CDRH) hosted the first of three town halls focused on biocompatibility and medical devices. This first session focused on recent updates to ISO 10993-1:2025, [...]

  • FDA Opens the Door on GenAI-Enabled Medical Devices: Why Quality Systems Need to Be Ready

    On August 18, 2026, FDA issued a discussion paper seeking public feedback on how the agency should approach regulation of generative AI-enabled medical devices. The paper asks for input on risk assessment, premarket evaluation, postmarket [...]

  • FDA’s TAP Pilot Expansion: Why Early FDA Engagement Requires Quality Readiness

    FDA’s Total Product Life Cycle Advisory Program (TAP) continues to expand, giving more medical device innovators the opportunity for earlier, more frequent engagement with FDA during development. As of FDA’s July 2026 TAP update, the [...]

  • FDA’s Proposed Registration Rule: What Distributed Manufacturing Means for Quality Oversight

    On July 10, 2026, FDA issued a proposed rule that would modernize drug manufacturing registration requirements. If finalized, the rule would create a streamlined registration pathway for distributed manufacturing establishments operating under a hub-and-spoke model. [...]

12Next

© 2012 - 2026 • Avada is a Website Builder for WordPress and eCommerce • All Rights Reserved • Developed by ThemeFusion

Page load link
Go to Top